Johnson & Johnson sells prescription drugs and medical devices through two divisions. The pharmaceuticals division focuses on treatments for immune disorders, cancer, and neurological conditions. The medtech division makes surgical tools, orthopedic implants, cardiovascular devices, and vision care products. Customers are hospitals, clinics, physicians, and patients, with revenue coming from product sales to healthcare systems and through insurance reimbursement. The consumer brands business (Kenvue) was spun off in 2023, so J&J is now purely a pharmaceutical and medical device company. Roughly half of revenue comes from the U.S., with the rest spread internationally.
Employees140,800IPOSep 25, 1944SIC2834HQOne Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
to
Financials
Profitability
Metric
Current
Margins
Gross Margin
67.9%
Operating Margin
26.8%
EBITDA Margin
34.7%
Net Margin
21.5%
OCF Margin
28.2%
FCF Margin
22.7%
Returns on Capital
ROE
25.9%
ROA
10.7%
ROIC
14.1%
ROCE
18.3%
ROC (Greenblatt)
114.6%
3Y ROIIC
64.0%
Consistency
Years Profitable / 10Y
10
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
29.61
Forward P/E
22.06
P/E ex-NRI
24.41
Shiller P/E (CAPE)
31.63
Cash Flow Multiples
P/FCF
28.01
P/OCF
22.57
P/Owner Earnings
29.16
FCF Yield
3.61%
Enterprise Value Multiples
EV / EBIT
24.57
EV / Forward EBIT
21.85
EV / EBITDA
18.96
EV / Forward EBITDA
17.29
EV / Revenue
6.58
EV / Forward Revenue
6.40
Asset / Sales
P/S
6.38
P/B
7.24
P/Tangible Book
—
Growth-Adjusted
PEG
2.60
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
2.06%
Forward Dividend Yield
2.11%
3Y Dividend Growth
4.9%
Payout Ratio
0.50
5Y Yield on Cost
2.62%
Buybacks & Dilution
3Y Buyback Ratio
2.70%
5Y Share Change
−9.1%
Combined
Shareholder Yield
2.46%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
0.58
Gross Debt / EBITDA
1.44
Cash / Debt
0.42
Equity / Assets
0.42
Coverage
Interest Coverage
25.94
Short-Term Liquidity
Current Ratio
1.09
Quick Ratio
0.81
Cash Ratio
0.38
Composite Scores
Piotroski F-Score
6
Altman Z-Score
4.21
Split History
Date
Split
2001-06-13
2:1
1996-06-12
2:1
1992-06-10
2:1
1989-05-11
2:1
1981-05-19
3:1
1970-05-18
3:1
Ex-date
Amount
Pay date
2026-08-25
$1.34
2026-09-08
2026-05-26
$1.34
2026-06-09
2026-02-24
$1.3
2026-03-10
2025-11-25
$1.3
2025-12-09
2025-08-26
$1.3
2025-09-09
2025-05-27
$1.3
2025-06-10
2025-02-18
$1.24
2025-03-04
2024-11-26
$1.24
2024-12-10
2024-08-27
$1.24
2024-09-10
2024-05-20
$1.24
2024-06-04
10 of 219
View allDate
Transcript
Type
2026-08-03
Johnson & Johnson Investor Conference Call Transcript
Corporate Presentation
2026-07-15
Q2 2026 Johnson & Johnson Earnings Call Transcript
Earnings Call
2026-06-09
Johnson & Johnson at Goldman Sachs Healthcare Conference Transcript
Conference Presentations
2026-05-27
Johnson & Johnson at Bernstein Strategic Decisions Conference Transcript
Conference Presentations
2026-05-19
Johnson & Johnson at RBC Capital Markets Global Healthcare Conference Transcript
Conference Presentations
2026-05-12
Johnson & Johnson at Bank of America Global Healthcare Conference Transcript
Conference Presentations
2026-04-14
Q1 2026 Johnson & Johnson Earnings Call Transcript
Earnings Call
2026-03-10
Johnson & Johnson at Barclays Global Healthcare Conference Transcript
Conference Presentations
2026-03-03
Johnson & Johnson at TD Cowen Healthcare Conference Transcript
Conference Presentations
2026-01-21
Q4 2025 Johnson & Johnson Earnings Call Transcript
Earnings Call
10 of 111
5-Step DuPont Analysis
ROE %
25.74%
×
×
Net Margin %
21.48%
×
×
Operating Margin %
26.81%
Operating Income
$26.26B
÷
Revenue
$97.93B
×
Tax Burden
0.8349
Net Income
$21.04B
÷
Pretax Income
$25.20B
×
Interest Burden
0.9596
Pretax Income
$25.20B
÷
Operating Income
$26.26B
×
Asset Turnover
0.50
÷
Revenue
$97.93B
÷
Average Total Assets
$197.22B
Begin Total Assets
$193.39B
End Total Assets
$201.06B
×
Equity Multiplier
2.41
÷
Avg Total Assets
$197.22B
÷
Avg Stockholders Equity
$81.72B
Begin Equity
$78.47B
End Equity
$84.97B
Top institutional holders
Q2 2026| Holder | Shares | % Owned | Chg. shares | |
|---|---|---|---|---|
| BlackRock, Inc. | 212.1M | 8.81% | -1.3M | $53.87B |
| VANGUARD CAPITAL MANAGEMENT LLC | 157.2M | 6.53% | +621.0K | $39.93B |
| STATE STREET CORP | 133.8M | 5.55% | +299.7K | $33.98B |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 64.4M | 2.67% | +856.4K | $16.35B |
| GEODE CAPITAL MANAGEMENT, LLC | 59.1M | 2.45% | -78.4K | $14.97B |
| JPMORGAN CHASE & CO | 58.3M | 2.42% | -4.8M | $15.07B |
| MORGAN STANLEY | 44.8M | 1.86% | +87.1K | $11.38B |
| NORGES BANK | 31.8M | 1.32% | new | $8.08B |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 31.6M | 1.31% | 0 | $8.02B |
| NORTHERN TRUST CORP | 28.8M | 1.20% | -527.6K | $7.31B |
10 of 4,721
View allTop insider holdings
as reported| Insider | Shares held | % Owned | |
|---|---|---|---|
| Duato JoaquinOfficer | 306.8K | 0.0127% | $78.41M |
| Taubert Jennifer LOfficer | 194.5K | 0.0081% | $49.69M |
| Wengel Kathryn EOfficer | 114.3K | 0.0047% | $29.21M |
| Wolk Joseph JOfficer | 82.8K | 0.0034% | $21.17M |
| Swanson James D.Officer | 25.7K | 0.0011% | $6.57M |
| Schmid TimothyOfficer | 25.4K | 0.0011% | $6.50M |
| REED JOHN COfficer | 24.9K | 0.0010% | $6.37M |
| Decker Robert JOfficer | 23.7K | 0.0010% | $6.05M |
| Broadhurst VanessaOfficer | 23.0K | 0.0010% | $5.88M |
| Mulholland KristenOfficer | 19.8K | 0.0008% | $5.07M |
10 of 15
View allRecent insider activity
through Sep 2, 2026| Insider | Action | Shares | Date | |
|---|---|---|---|---|
| Schmid TimothyOfficer | Option Exercise (Rule 16b-3 Exempt) | +11.1K | $1.46M | Sep 2, 2026 |
| Schmid TimothyOfficer | Open-Market or Private Sale | -11.1K | $3.04M | Sep 2, 2026 |
| Schmid TimothyOfficer | Option Exercise (Rule 16b-3 Exempt) | +22.5K | $3.41M | Sep 2, 2026 |
| Schmid TimothyOfficer | Open-Market or Private Sale | -22.5K | $6.19M | Sep 2, 2026 |
| Taubert Jennifer LOfficer | Option Exercise (Rule 16b-3 Exempt) | +15.0K | $1.74M | Aug 17, 2026 |
| Taubert Jennifer LOfficer | Open-Market or Private Sale | -15.0K | $3.95M | Aug 17, 2026 |
| Duato JoaquinOfficer | Option Exercise (Rule 16b-3 Exempt) | +123.3K | $14.26M | Aug 13, 2026 |
| Duato JoaquinOfficer | Open-Market or Private Sale | -21.0K | $5.50M | Aug 13, 2026 |
| Duato JoaquinOfficer | Open-Market or Private Sale | -102.3K | $26.70M | Aug 13, 2026 |
| Forminard ElizabethOfficer | Option Exercise (Rule 16b-3 Exempt) | +9.3K | $1.23M | Aug 6, 2026 |
10 of 2,318
View all